Lymphoid Neoplasm, NGS, Varies

ALL; CLL; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Hairy Cell Leukemia; Splenic Marginal Zone Lymphoma; T-cell Lymphoma

21 days

Next Generation Sequencing (NGS)

Accredited NRL Laboratory

Contact Technical Support

Lymphoid Neoplasm NGS Testing, a comprehensive DNA-based next-generation sequencing assay covering 112 genes, designed to support precision diagnostics in lymphoid malignancies. This assay provides integrated molecular profiling aligned with the WHO Classification of Haematolymphoid Tumours (5th Edition) and NCCN clinical guidelines, supporting diagnostic classification, prognostic stratification, and therapeutic decision-making across a broad spectrum of lymphoid neoplasms, including:
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL)
• Diffuse Large B-Cell Lymphoma (DLBCL)
• Follicular Lymphoma
• Hairy Cell Leukemia
• Splenic Marginal Zone Lymphoma
• T-Cell Lymphomas

Bone Marrow (BM) Aspirate; Peripheral Blood (PB); extracted gDNA; Bone Marrow Aspirate Smears (preferably unstained); Fresh or FFPE tissue

BM, 3mL; PB, 5mL; BM Aspirate Smears, 5 slides; gDNA, 200ng

EDTA for BM and PB; Fresh tissue in saline; FFPE blocks

No special preparation is required for this test. You may eat, drink, and take your medications as normal, unless instructed otherwise by your healthcare provider.

This test does not require any special collection or pre-analytical handling. Follow routine specimen collection protocols.